Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of midazolam and ketamine is used for procedural sedation and analgesia, particularly in emergency departments and minor surgical or diagnostic procedures. Midazolam is a benzodiazepine that provides anxiolysis, amnesia, and sedation by enhancing the effect of the neurotransmitter GABA at the GABA-A receptor. Ketamine is a dissociative anesthetic that acts primarily as an NMDA receptor antagonist, producing analgesia, anesthesia, and amnesia while maintaining airway reflexes. The combination leverages the sedative and anxiolytic effects of midazolam with the potent analgesic properties of ketamine. This pairing can reduce adverse emergence reactions associated with ketamine alone while providing effective pain control and sedation[1][2][3][4][5]. It is considered safe when administered under medical supervision but may increase risks such as respiratory depression or excessive sedation[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on midazolam + ketamine.